Algeta

Algeta ASA is an oncology company focused on developing targeted therapies for cancer patients based on its alpha-pharmaceutical platform. Algeta's lead product candidate, Alpharadin, is a next-generation alpha-pharmaceutical based on radium-223, currently in Phase III clinical trials as a potential new treatment for bone metastases in patients with hormone-refractory prostate cancer (HRPC). Alpharadin demonstrated in a comprehensive Phase II clinical program that it can extend patient survival, improve quality of life by controlling pain, and provide placebo-like safety.